Clinical trials: Melanoma Metastatic
Metastatic Malignant Melanoma
A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma
This study is designed to assess the safety and efficacy of a combination of ipilimumab and fotemustine in Patients with Unresectable Locally Advanced or Metastatic Malignant Melanoma.
- Trial name
- NIBIT-M1 (NCT01654692)
- Testing
- Ipilimumab and Fotemustine
- Where
- 7 sites in Italy
- Volunteers
- 86 people
- Sponsor
- Italian Network for Tumor Biotherapy
Melanoma
A Study to Test the Benefit of a New Anti-cancer Treatment in Patients With Unresectable Advanced Melanoma
The objective of this study is to evaluate the clinical activity of the GSK2132231A immunotherapeutic in patients with MAGE-A3 positive unresectable metastatic melanoma presenting with the predictive gene signature.
- Trial name
- PREDICT (NCT00942162)
- Testing
- Immunotherapeutic GSK2132231A
- Where
- 63 sites in United States, France and 6 more
- Volunteers
- 125 people
- Sponsor
- GlaxoSmithKline
Melanoma
Active Specific Intranodal Immunotherapy of Recombinant Vaccinia Virus in Locally Advanced to Metastatic Melanoma
The purpose of this study is to assess intranodal immunotherapy in locally advanced to metastatic melanoma patients (American Joint Committee on Cancer [AJCC] stages IIb to IV).
- Trial name
- NCT00116597
- Testing
- Intranodal immunization with a recombinant vaccinia virus expressing 5 transgenes, Intranodal booster immunizations with synthetic melanoma associated epitopes
- Where
- Switzerland
- Volunteers
- 15 people
- Sponsor
- University Hospital, Basel, Switzerland
Uveal Melanoma, Metastatic
Low Dose Dexamethasone for the Prevention of Cytokine Release Syndrome Associated With Tebentafusp
The goal of this clinical trial is to learn if a low dose of dexamethasone can prevent cytokine release syndrome in participants treated with tebentafusp for advanced uveal melanoma.
- Trial name
- LODEXA (NCT07803562)
- Testing
- Dexamethasone
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of California, San Diego
Melanoma Stage III, Melanoma Stage IV
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients
The trial aims to evaluate the efficacy of single agent L19IL2, single agent L19TNF, and combination L19IL2+L19TNF given concurrently with anti-PD1 therapy compared to historical control of anti-PD-1 re-challenge alone for…
- Trial name
- INTACT/MeRCI (NCT06284590)
- Testing
- L19IL2, L19TNF, L19IL2/L19TNF
- Where
- 7 sites in United States, Germany and 1 more
- Volunteers
- 162 people
- Sponsor
- Philogen S.p.A.
Melanoma (Skin)
Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Vaccines made from melanoma cells may make the body build an immune response to kill tumor cells. Biological therapies such as interferon gamma and interleukin-2 use different ways to stimulate the immune system and…
- Trial name
- NCT00006113
- Testing
- MART-1 antigen, aldesleukin, gp100 antigen
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Southern California
Mucosal Lentiginous Melanoma, Acral Lentiginous Malignant Melanoma
SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma
The purpose of this study is to evaluate how effective Sunitinib works in treating acral lentiginous and mucosal melanoma which has spread beyond the local region.
- Trial name
- NCT00577382
- Testing
- Sunitinib
- Where
- 5 sites in United States
- Volunteers
- 52 people
- Sponsor
- Dana-Farber Cancer Institute
Stage IIIB Melanoma, Stage IIIC Melanoma
Dinaciclib in Treating Patients With Stage III-IV Melanoma
This is a phase I/II trial is studying the side effects and best dose of dinaciclib and to see how well it works in treating patients with advanced melanoma.
- Conditions
- Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
- Trial name
- NCT01026324
- Testing
- dinaciclib, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Melanoma
Imatinib and Toripalimab in Patients With Locally Advanced/Metastatic Melanoma Harbored With CKIT Mut
It is a single-center, single-arm Phase II clinical study. This clinical trial aimed to evaluate the PFS of imatinib combined with toripalimab in stage III unresectable and stage IV melanoma with CKIT gene mutation.
- Trial name
- NCT05274438
- Testing
- JS001+Imatinib mesylate
- Where
- China
- Volunteers
- 37 people
- Sponsor
- Peking University Cancer Hospital & Institute
Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Participants of this study will have a diagnosis of a solid tumor cancer that has come back to its original location or spread beyond its original location (advanced), came back (relapsed) or worsened (refractory) after standard…
- Conditions
- Cutaneous Squamous Cell Carcinoma, SCC - Squamous Cell Carcinoma, Basal Cell Carcinoma, BCC
- Trial name
- NCT05859074
- Testing
- MQ719, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 56 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Metastatic Melanoma
A Study Using Tumor-Reactive Autologous Tumor Infiltrating Lymphocytes (TIL) in Metastatic Melanomas
The purpose of this protocol is to determine whether autologous TIL infused in conjunction with systemic high-dose IL-2 after non-myeloablative chemotherapy with cyclophosphamide and fludarabine can cause consistent and durable…
- Trial name
- TIL (NCT02375984)
- Testing
- Tumor Infiltrating Lymphocytes (TIL)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Saint John's Cancer Institute
Vitiligo, Skin Melanoma
Defining the Role of the Skin Microbiome in Immune-related Adverse Events
The skin microbiome has been implicated in several cutaneous autoimmune pathologies such as psoriasis and atopic dermatitis. However, its role in vitiligo and vitiligo lesions occuring in patients receiving anti-PD-1 for…
- Trial name
- SKINBIOTA (NCT04734704)
- Testing
- skin swabs at lesional and non-lesional sites, skin swabs on skin
- Where
- France
- Volunteers
- 57 people
- Sponsor
- University Hospital, Bordeaux
Melanoma
Pfizer PF-06688992 in Patients With Stage III or Stage IV Melanoma
The purpose of this research study is to learn about the safety and effectiveness of the study drug, PF-06688992. Before this study, PF-06688992 has never been given to people.
- Trial name
- NCT03159117
- Testing
- PF-06688992
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Malignant Melanoma
Prevention of Recurrence and Metastasis in Genetically High-Risk Melanomas
The purpose of this study is to determine whether a medication, fluvastatin, can change melanoma to a state that is less likely to metastasize or recur.
- Trial name
- NCT04285749
- Testing
- Fluvastatin, RNA-sequencing, Gene expression profiling
- Sponsor
- Case Comprehensive Cancer Center
Advanced or Metastatic Solid Tumors, Lung Cancer
A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors
This research study is studying a new drug, NC318, as a possible treatment for advanced or metastatic solid tumors.
- Conditions
- Advanced or Metastatic Solid Tumors, Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT03665285
- Testing
- NC318
- Where
- 6 sites in United States
- Volunteers
- 109 people
- Sponsor
- NextCure, Inc.
Melanoma, Neoplasm Metastasis
Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.
Subjects are randomized to one of two treatment arms. All subjects are screened for eligibility within 28 days prior to randomization. The study consists of a treatment phase and a follow-up phase.
- Trial name
- NCT00057616
- Testing
- CC-5013
- Where
- 49 sites in Australia, Estonia and 7 more
- Volunteers
- 274 people
- Sponsor
- Celgene
Melanoma
Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma
The goal of this clinical research study is to find the highest tolerated dose of rAd.CD40L (also called ISF35) when given with pembrolizumab to patients with melanoma.
- Trial name
- NCT02719015
- Testing
- rAd.CD40L, Pembrolizumab
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Neoplasm in the Spine
SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine
This phase I pilot trial studies the side effects of stereotactic radiosurgery and nivolumab in treating patients with newly diagnosed melanoma that has spread to the brain or spine.
- Conditions
- Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Neoplasm in the Spine, Stage IV Skin Melanoma
- Trial name
- NCT02716948
- Testing
- Laboratory Biomarker Analysis, Nivolumab, Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Colorectal Cancer Metastatic, Metastatic Melanoma
The Jules Bordet Institute Molecular Profiling Program Feasibility Trial
Prior to the use of genomic tests for patient inclusion in clinical trials, it is essential for the Jules Bordet Institute (JBI) to pilot the logistical and technical aspects by examining the feasibility and turnaround time of…
- Conditions
- Colorectal Cancer Metastatic, Metastatic Melanoma, Metastatic Non-Small Cell Lung Carcinoma
- Trial name
- PRECISION-F (NCT01932489)
- Testing
- Biopsy of a metastatic lesion.
- Where
- Belgium
- Volunteers
- 35 people
- Sponsor
- Jules Bordet Institute
Urothelial Carcinoma, Head and Neck Cancer
MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers
This Phase 1 study is designed as a cell dose escalation trial in HLA-A*02:01 and HLA-A*02:06 subjects with MAGE-A10 positive urothelial, melanoma or head and neck tumors.
- Conditions
- Urothelial Carcinoma, Head and Neck Cancer, Melanoma, Bladder Urothelial Carcinoma
- Trial name
- NCT02989064
- Testing
- Autologous genetically modified MAGE A10ᶜ⁷⁹⁶T cells
- Where
- 11 sites in United States, Canada and 1 more
- Volunteers
- 10 people
- Sponsor
- Adaptimmune